Navigation Links
NBTY Reports Second Quarter Results
Date:4/23/2009

RONKONKOMA, N.Y., April 23 /PRNewswire-FirstCall/ -- NBTY, Inc. (NYSE: NTY) (www.NBTY.com), a leading global manufacturer and marketer of nutritional supplements, today announced results for the fiscal second quarter and first six months ended March 31, 2009.

For the fiscal second quarter ended March 31, 2009, net sales were $596 million compared to $533 million for the fiscal second quarter ended March 31, 2008, an increase of $63 million or 12%. Included in this total are net sales of $23 million from Julian Graves, acquired in the fiscal fourth quarter of 2008. The Leiner Health Products business, which was acquired in July 2008, has been fully integrated into NBTY operations; accordingly its sales can no longer be separately identified.

Net income for the fiscal second quarter ended March 31, 2009 was $23 million, or $0.37 per diluted share, compared to $44 million, or $0.67 per diluted share, for the fiscal second quarter ended March 31, 2008.

The decline in net income for the fiscal second quarter of 2009 reflects lower gross profit margins due to higher raw material costs which were not offset by higher prices charged to customers and the impact of a stronger US dollar as compared to the British Pound Sterling. The British pound sterling declined 27% compared to the prior like quarter. Without fluctuations in foreign exchange rates, earnings per diluted share would have been $0.09 higher for the fiscal second quarter of 2009.

Adjusted EBITDA for the fiscal second quarter of 2009 was $62 million, compared to $84 million for the fiscal second quarter of 2008. At March 31, 2009, working capital was $530 million, a decrease of $43 million compared to September 30, 2008. At March 31, 2009, total assets were $1.8 billion, and book value per share was $15.81.

Since October 1, 2008, the Company repaid $15 million under its term loan and $55 million under its revolving credit agreement. As of March 31, 2009, $320 million remained undrawn under the Company's $325 million Revolving Credit Facility. The Company is in compliance with all of its covenants under outstanding credit facilities.

For the six months ended March 31, 2009, net sales were $1.3 billion compared to $1.0 billion for the six months ended March 31, 2008, an increase of $213 million or 20%.

Net income for the six months ended March 31, 2009 was $37 million, or $0.58 per diluted share, compared to $90 million, or $1.34 per diluted share, for the six months ended March 31, 2008. The decrease in net income for the six months ended March 31, 2009 reflects the aforementioned lower gross profit margins, decreases in foreign exchange rates and previously announced costs associated with the write off and termination of the information technology programs in our Direct Response business, which programs were ineffective and uneconomical.

Adjusted EBITDA for the six months ended March 31, 2009 was $116 million, compared to $171 million for the six months ended March 31, 2008.

Overall gross profit margins for the fiscal second quarter of 2009 decreased to 42% from 51% for the fiscal second quarter of 2008. As previously discussed, a portion of this decrease was anticipated due to lower gross margins on Leiner private label business. Additional cost pressures occurred at the time of the Leiner acquisition in July 2008, when Leiner inventory levels were not adequate to maintain customer fulfillment levels. At the same time, certain raw material costs were increasing due to tight supply and inflationary pressures. In order to maintain adequate customer fulfillment levels, the Company was forced to purchase products at these higher costs. These conditions continued to negatively impact results for the last two quarters. The Company believes operations are stabilizing.

OPERATIONS FOR THE FISCAL SECOND QUARTER ENDED MARCH 31, 2009

Net sales for the Wholesale/US Nutrition division, which markets various brands including Nature's Bounty, Osteo Bi-Flex, Rexall, Ester-C and Leiner products, increased $90 million, or 35%, to $350 million. Since acquiring Leiner, the Company has eliminated in excess of $30 million in annualized non-manufacturing costs.

Gross profit for the Wholesale operation decreased to 27% from 41% for the prior like quarter. Operating results were adversely affected by higher raw material costs which were not offset by higher prices charged to wholesale customers. While the gross profit percentage decreased during this period, the Company continued to increase its market share. The Nielsen Company tracks industry-wide sales of vitamins, minerals, herbs and other supplements in the food, drug and mass market sectors. For the thirteen week period ended March 28, 2009, Nielsen reported an increase in the entire category of 8%. According to Nielsen, for that same period, the Company's Wholesale brands reported a 10% increase.

The Wholesale/US Nutrition division utilizes valuable consumer preference sales data generated by the Company's Vitamin World retail stores and Puritan's Pride Direct Response/E-Commerce operations to empower its wholesale customers with this latest data. The Vitamin World stores are used as a laboratory for new ideas and are an effective tool in determining and monitoring consumer preferences. This information, as well as scanned sales data from the Vitamin World stores, is shared on a real time basis with our wholesale customers to give them a competitive advantage.

Net sales for the North American Retail division, comprised of Vitamin World Stores in the United States and LeNaturiste stores in Canada, were $52 million, unchanged from the prior like quarter. While operating in a difficult retail environment in the US and Canada, Vitamin World same store sales increased 4% for the fiscal second quarter of 2009. Vitamin World results seem to indicate that the new modernization of the stores has had a favorable impact on the US Stores.

Net sales at LeNaturiste decreased 18%, all attributable to a weaker Canadian dollar, and the division operated at a loss of $1 million. LeNaturiste will continue to focus on increasing gross margins by utilizing more in-house manufactured products and more targeted promotions.

During the fiscal second quarter of 2009, the North American Retail division closed 3 stores and added 3 new stores. At the end of the fiscal second quarter of 2009, the North American Retail division operated a total of 531 stores, consisting of 444 Vitamin World stores in the United States and 87 LeNaturiste stores in Canada. Vitamin World plans to add 3 stores and close 5 stores during the remainder of fiscal 2009.

European Retail net sales for the fiscal second quarter ended March 31, 2009 decreased $24 million, or 15% to $134 million compared to $158 million for the prior like quarter. Julian Graves recorded net sales of $23 million. European Retail division same store sales in local currency decreased 5% from the prior like period. On a monthly basis, in local currency, same store sales decreased 10% in both January and February but increased 4% in March.

As previously announced, the Julian Graves acquisition continues to be the subject of an inquiry from the UK Competition Commission for potential anti-trust implications. In conjunction with this inquiry, Julian Graves business has not been integrated with the Company's European operations and incurred a loss of $0.5 million during the fiscal second quarter ended March 31, 2009.

The European Retail division continues to leverage its premier status, high street locations and brand awareness in a difficult retail environment. The European Retail division consists of 531 Holland & Barrett stores, 345 Julian Graves stores and 31 GNC stores in the UK, 22 Nature's Way stores in Ireland, and 71 DeTuinen stores in the Netherlands, for a total of 1,000 stores in Europe. In addition, during the fiscal second quarter of 2009, Holland & Barrett opened 3 franchised stores in South Africa, for a total of 7 franchised stores in South Africa.

Net sales from Direct Response/E-Commerce operations for the fiscal second quarter of 2009 decreased $4 million, or 6% to $59 million from $63 million for the fiscal second quarter of 2008. As this division varies its promotional strategy throughout the fiscal year, its results should be viewed on an annual and not quarterly basis. For the fiscal second quarter of 2009, compared with the prior like quarter, gross profit percentage for this division increased 5% to 64%; average order size increased $8 to $78. This division was reorganized during the first fiscal quarter of 2009. Online sales represented 43% of total Direct Response/E-Commerce sales. Puritan's Pride is the leader in the Direct Response and E-Commerce sectors and continues to increase the number of products available via its catalog and web sites.

NBTY Chairman and CEO, Scott Rudolph, said: "Profitability for the quarter was affected by inflationary pressures and foreign exchange declines. We continue to garner greater market share and enhance our position as the global leader in the nutritional supplement industry. The overall success of NBTY, and its ability to generate long-term growth, reflects our commitment to providing the highest quality products to our customers."

ABOUT NBTY

NBTY is a leading global vertically integrated manufacturer, marketer and distributor of a broad line of high-quality, value-priced nutritional supplements in the United States and throughout the world. Under a number of NBTY and third party brands, the Company offers over 25,000 products, including products marketed by the Company's Nature's Bounty(R) (www.NaturesBounty.com), Vitamin World(R) (www.VitaminWorld.com), Puritan's Pride(R) (www.Puritan.com), Holland & Barrett(R) (www.HollandAndBarrett.com), Rexall(R) (www.Rexall.com), Sundown(R) (www.SundownNutrition.com), MET-Rx(R) (www.MetRX.com), Worldwide Sport Nutrition(R) (www.SportNutrition.com), American Health(R) (www.AmericanHealthUS.com), GNC (UK)(R) (www.GNC.co.uk), DeTuinen(R) (www.DeTuinen.nl), LeNaturiste(TM) (www.LeNaturiste.com), SISU(R) (www.SISU.com), Solgar(R) (www.Solgar.com), Good 'n' Natural(R) (www.goodnnatural.com), Home Health(TM) (www.homehealthus.com), Julian Graves, and Ester-C(R) (www.Ester-C.com) brands. NBTY routinely posts information that may be important to investors on its web site.

This release refers to non-GAAP financial measures, such as Adjusted EBITDA. "Adjusted EBITDA" is defined as net income, excluding the aggregate amount of all non-cash losses reducing net income, plus interest, taxes, depreciation and amortization. This non-GAAP financial measure is not prepared in accordance with generally accepted accounting principles and may be different from non-GAAP financial measures used by other companies. Non-GAAP financial measures should not be considered as a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. A reconciliation of the non-GAAP measure to the comparable GAAP measure is included in the attached financial tables. Management believes the presentation of Adjusted EBITDA is relevant and useful because Adjusted EBITDA is a measurement industry

analysts utilize when evaluating NBTY's operating performance. Management also believes Adjusted

EBITDA enhances an investor's understanding of NBTY's results of operations because it measures NBTY's operating performance exclusive of interest and non-cash charges for depreciation and amortization. Management also provides this non-GAAP measurement as a way to help investors better understand its core operating performance, enhance comparisons of NBTY's core operating performance from period to period and to allow better comparisons of NBTY's operating performance to that of its competitors.

This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 with respect to our financial condition, results of operations and business. These forward-looking statements can be identified by the use of terminology such as "subject to," "believe," "expects," "plan," "project," "estimate," "intend," "may," "will," "should," "can," or "anticipates," or the negative thereof, or variations thereon, or comparable terminology, or by discussions of strategy. Although all of these forward looking statements are believed to be reasonable, they are inherently uncertain. Factors which may materially affect such forward-looking statements include: (i) slow or negative growth in the nutritional supplement industry; (ii) interruption of business or negative impact on sales and earnings due to acts of God, acts of war, terrorism, bio-

terrorism, civil unrest or disruption of mail service; (iii) adverse publicity regarding nutritional supplements; (iv) inability to retain customers of companies (or mailing lists) recently acquired; (v) increased competition; (vi) increased costs; (vii) loss or retirement of key members of management; (viii) increases in the cost of borrowings and/or unavailability of additional debt or equity capital; (ix) unavailability of, or inability to consummate, advantageous acquisitions in the future, including those that may be subject to bankruptcy approval or the inability of NBTY to integrate acquisitions into the mainstream of its business; (x) changes in general worldwide economic and political conditions in the markets in which NBTY may compete from time to time; (xi) the inability of NBTY to gain and/or hold market share of its wholesale and/or retail customers anywhere in the world; (xii) unavailability of electricity in certain geographical areas; (xiii) the inability of NBTY to obtain and/or renew insurance and/or the costs of the same; (xiv) exposure to and expense of defending and resolving product liability and intellectual property claims and other litigation; (xv) the ability of NBTY to successfully implement its business strategy; (xvi) the inability of NBTY to manage its retail, wholesale, manufacturing and other operations efficiently; (xvii) consumer acceptance of NBTY's products; (xviii) the inability of NBTY to renew leases for its retail locations; (xix) the inability of NBTY's retail stores to attain or maintain profitability; (xx) the absence of clinical trials for many of NBTY's products; (xxi) sales and earnings volatility and/or trends for the Company and its market segments; (xxii) the efficacy of NBTY's Internet and on-line sales and marketing strategies; (xxiii) fluctuations in foreign currencies, including the British pound, the Euro and the Canadian dollar; (xxiv) import-export controls on sales to foreign countries; (xxv) the inability of NBTY to secure favorable new sites for, and delays in opening, new retail and manufacturing locations; (xxvi) introduction of and compliance with new federal, state, local or foreign legislation or regulation or adverse determinations by regulators anywhere in the world (including the banning of products) and more particularly Good Manufacturing Practices in the United States, the Food Supplements Directive and Traditional Herbal Medicinal Products Directive in Europe and Section 404 requirements of the Sarbanes-Oxley Act of 2002; (xxvii) the mix of NBTY's products and the profit margins thereon; (xxviii) the availability and pricing of raw materials; (xxix) risk factors discussed in NBTY's filings with the U.S. Securities and Exchange Commission; (xxx) adverse effects on NBTY as a result of increased energy prices and potentially reduced traffic flow to NBTY's retail locations; (xxxi) adverse tax determinations; (xxxii) the loss of a significant customer of the Company; (xxxiii) potential investment losses as a result of liquidity conditions; and (xxxiv) other factors beyond the Company's control.

Readers are cautioned not to place undue reliance on forward-looking statements. NBTY cannot guarantee future results, trends, events, levels of activity, performance or achievements. NBTY does not undertake and specifically declines any obligation to update, republish or revise forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrences of unanticipated events.

Consequently, such forward-looking statements should be regarded solely as NBTY's current plans, estimates and beliefs.

(TABLES FOLLOW)

                                        NBTY, INC.
                        CONDENSED CONSOLIDATED STATEMENTS OF INCOME
                                        (UNAUDITED)

    (In thousands, except per share amounts)

                                                          Three months
                                                         ended March 31,
                                                      2009            2008

    Net sales                                     $595,553        $532,518

    Costs and expenses:
      Cost of sales                                343,644         261,284
      Advertising, promotion and catalog            33,028          39,007
      Selling, general and administrative          174,657         166,409
                                                   551,329         466,700

    Income from operations                          44,224          65,818

    Other income (expense):
       Interest                                     (8,888)         (3,657)
       Miscellaneous, net                              279           3,786
                                                    (8,609)            129

    Income before provision for income taxes        35,615          65,947

    Provision for income taxes                      12,545          21,721

    Net income                                     $23,070         $44,226



    Net income per share:
      Basic                                          $0.37           $0.69
      Diluted                                        $0.37           $0.67

    Weighted average common shares outstanding:
      Basic                                         61,600          64,102
      Diluted                                       62,948          65,817



                                        NBTY, INC.
                       CONDENSED CONSOLIDATED STATEMENTS OF INCOME
                                       (UNAUDITED)

    (In thousands, except per share amounts)

                                                          Six months
                                                         ended March 31,
                                                      2009            2008

    Net sales                                   $1,256,105      $1,043,376

    Costs and expenses:
      Cost of sales                                732,147         501,615
      Advertising, promotion and catalog            64,319          73,176
      Selling, general and administrative          370,557         334,531
      IT project termination costs                   8,647               -
                                                 1,175,670         909,322

    Income from operations                          80,435         134,054

    Other income (expense):
       Interest                                    (18,377)         (7,519)
       Miscellaneous, net                           (5,356)          8,673
                                                   (23,733)          1,154

    Income before provision for income taxes        56,702         135,208

    Provision for income taxes                      20,157          45,160

    Net income                                     $36,545         $90,048



    Net income per share:
      Basic                                          $0.59           $1.37
      Diluted                                        $0.58           $1.34

    Weighted average common shares outstanding:
      Basic                                         61,600          65,510
      Diluted                                       63,043          67,313



                                                  SALES
                                               (Unaudited)
                                           THREE MONTHS ENDED
                                                MARCH 31,

                                                                Percentage
    (In thousands)                    2009             2008       Change

    Wholesale / US Nutrition      $349,801         $259,363          35%

    North American Retail           51,916           51,904           0%

    European Retail                134,438          158,070         -15%

    Direct Response / E-Commerce    59,398           63,181          -6%

    Total                         $595,553         $532,518          12%



                                              GROSS PROFIT
                                               PERCENTAGES
                                               (Unaudited)
                                           THREE MONTHS ENDED
                                                MARCH 31,

                                                                Increase
                                      2009             2008    - Decrease

    Wholesale / US Nutrition            27%              41%        -14%

    North American Retail               66%              62%          4%

    European Retail                     63%              61%          2%

    Direct Response / E-Commerce        64%              59%          5%

    Total                               42%              51%         -9%



                                                    SALES
                                                 (Unaudited)
                                              SIX MONTHS ENDED
                                                  MARCH 31,

                                                                Percentage
    (In thousands)                    2009             2008       Change


    Wholesale / US Nutrition      $756,768         $518,298          46%

    North American Retail          100,354          108,086          -7%

    European Retail                290,464          316,666          -8%

    Direct Response / E-Commerce   108,519          100,326           8%

    Total                       $1,256,105       $1,043,376          20%



                                                GROSS PROFIT
                                                 PERCENTAGES
                                                 (Unaudited)
                                              SIX MONTHS ENDED
                                                  MARCH 31,

                                                                Increase
                                      2009             2008  - Decrease


    Wholesale / US Nutrition            27%              42%        -15%

    North American Retail               67%              60%          7%

    European Retail                     63%              62%          1%

    Direct Response / E-Commerce        62%              60%          2%

    Total                               42%              52%        -10%



                                        ADJUSTED EBITDA**
                      Reconciliation of GAAP Measures to Non-GAAP Measures
                                           (Unaudited)
    (In thousands)
                                              THREE MONTHS ENDED
                                                MARCH 31, 2009

                    Pretax      Depreciation
                    Income          and                    Non-cash   Adjusted
                    (Loss)      amortization    Interest   charges    EBITDA**

    Wholesale /
     US Nutrition   $30,084        $3,586          $-        $(74)    $33,596

    North American
     Retail             914           745                      23       1,682

    European Retail  20,318         3,403                      38      23,759

    Direct Response /
     E-Commerce      21,198         1,267                     (62)     22,403

    Segment Results  72,514         9,001           -         (75)     81,440

    Corporate /
     Manufacturing  (36,899)        8,278       8,888         442     (19,291)

    Total           $35,615       $17,279      $8,888        $367     $62,149




                                              THREE MONTHS ENDED
                                                MARCH 31, 2008

                    Pretax      Depreciation
                    Income          and                    Non-cash   Adjusted
                    (Loss)      amortization    Interest   charges    EBITDA**

    Wholesale /
     US Nutrition   $41,507        $2,578          $-         $48     $44,133

    North American
     Retail             522           804                      16       1,342

    European Retail  34,266         2,970                      41      37,277

    Direct Response /
     E-Commerce      15,750         1,374                      20      17,144

    Segment Results  92,045         7,726           -         125      99,896

    Corporate /
     Manufacturing  (26,098)        5,998       3,657         393     (16,050)

    Total           $65,947       $13,724      $3,657        $518     $83,846


    **  SINCE ADJUSTED EBITDA IS NOT A MEASURE OF PERFORMANCE CALCULATED IN
    ACCORDANCE WITH U.S. GENERALLY ACCEPTED ACCOUNTING PRINCIPLES ("GAAP"), IT
    SHOULD NOT BE CONSIDERED IN ISOLATION OF, OR AS A SUBSTITUTE FOR OR
    SUPERIOR TO, OTHER MEASURES OF FINANCIAL PERFORMANCE PREPARED IN
    ACCORDANCE WITH GAAP, SUCH AS OPERATING INCOME, NET INCOME AND CASH FLOWS
    FROM OPERATING ACTIVITIES.  IN ADDITION, THE COMPANY'S DEFINITION OF
    ADJUSTED EBITDA IS NOT NECESSARILY COMPARABLE TO SIMILARLY TITLED MEASURES
    REPORTED BY OTHER COMPANIES.



                                        ADJUSTED EBITDA**
                      Reconciliation of GAAP Measures to Non-GAAP Measures
                                           (Unaudited)
    (In thousands)
                                               SIX MONTHS ENDED
                                                MARCH 31, 2009

                    Pretax      Depreciation
                    Income          and                    Non-cash   Adjusted
                    (Loss)      amortization    Interest   charges    EBITDA**

    Wholesale /
     US Nutrition   $72,098        $7,310          $-        $(27)    $79,381

    North American
     Retail           1,161         1,497           -          47       2,705

    European Retail  46,489         6,964           -          90      53,543

    Direct Response /
     E-Commerce      23,403         2,532           -       4,623      30,558

    Segment Results 143,151        18,303           -       4,733     166,187

    Corporate /
     Manufacturing  (86,449)       16,497      18,377       1,003     (50,572)

    Total           $56,702       $34,800     $18,377      $5,736    $115,615





                                               SIX MONTHS ENDED
                                                MARCH 31, 2008

                    Pretax      Depreciation
                    Income          and                    Non-cash   Adjusted
                    (Loss)      amortization    Interest   charges    EBITDA**

    Wholesale /
     US Nutrition   $95,488        $5,272          $-         $48    $100,808

    North American
     Retail            (342)        1,654           -         366       1,678

    European Retail  69,333         6,032           -          41      75,406

    Direct Response /
     E-Commerce      22,872         2,740           -          20      25,632

    Segment Results 187,351        15,698           -         475     203,524

    Corporate /
     Manufacturing  (52,143)       11,957       7,519         393     (32,274)

    Total          $135,208       $27,655      $7,519        $868    $171,250


    **   SINCE ADJUSTED EBITDA IS NOT A MEASURE OF PERFORMANCE CALCULATED IN
    ACCORDANCE WITH U.S. GENERALLY ACCEPTED ACCOUNTING PRINCIPLES ("GAAP"), IT
    SHOULD NOT BE CONSIDERED IN ISOLATION OF, OR AS A SUBSTITUTE FOR OR
    SUPERIOR TO, OTHER MEASURES OF FINANCIAL PERFORMANCE PREPARED IN
    ACCORDANCE WITH GAAP, SUCH AS OPERATING INCOME, NET INCOME AND CASH FLOWS
    FROM OPERATING ACTIVITIES.  IN ADDITION, THE COMPANY'S DEFINITION OF
    ADJUSTED EBITDA IS NOT NECESSARILY COMPARABLE TO SIMILARLY TITLED MEASURES
    REPORTED BY OTHER COMPANIES.



                                       NBTY, Inc.
                        Condensed Consolidated Balance Sheets
                                       (Unaudited)

    (In thousands, except per share amounts)

                                                 March 31,      September 30,
                                                   2009              2008
    Current assets:
      Cash and cash equivalents                 $43,801          $ 90,180
      Accounts receivable, net                  134,111           122,878
      Inventories                               613,401           585,239
      Deferred income taxes                      25,300            25,098
      Other current assets                       36,587            75,971

         Total current assets                   853,200           899,366

    Property, plant and equipment, net          394,645           419,066
    Goodwill                                    323,337           342,379
    Intangible assets, net                      217,945           230,424
    Other assets                                 37,151            45,123

        Total assets                         $1,826,278        $1,936,358

    Current liabilities:
      Current portion of long-term debt         $32,077           $33,309
      Accounts payable                          156,256           120,620
      Accrued expenses and other current
       liabilities                              134,817           172,035
        Total current liabilities               323,150           325,964

    Long-term debt, net of current portion      464,010           538,402
    Deferred income taxes                        32,992            49,139
    Other liabilities                            32,366            24,657
        Total liabilities                       852,518           938,162

    Commitments and contingencies

    Stockholders' equity:

    Common stock, $0.008 par; authorized
       175,000 shares; issued and outstanding
       61,600 and 61,599 shares at March 31,
       2009 and September 30, 2008, respectively    493               493
      Capital in excess of par                  142,065           140,990
      Retained earnings                         875,613           839,068
      Accumulated other comprehensive (loss)
       income                                   (44,411)           17,645
        Total stockholders' equity              973,760           998,196

    Total liabilities and stockholders'
     equity                                  $1,826,278        $1,936,358




                                        NBTY, INC.
                      CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
                                       (UNAUDITED)
    (In thousands)
                                                         Six Months
                                                       ended March 31,
                                                   2009              2008
    Cash flows from operating activities:
    Net income                                  $36,545           $90,048
    Adjustments to reconcile net income to
     cash provided by operating activities:
       Impairments and disposals of property,
        plant and equipment                         688               482
       Depreciation and amortization             34,800            27,655
       IT project termination costs               4,667                 -
       Foreign currency transaction loss (gain)   6,669           (1,385)
       Stock-based compensation                   1,069               518
       Amortization of deferred charges             631               372
       Allowance for doubtful accounts              850             (174)
       Inventory reserves                         7,177             2,465
       Deferred income taxes                        383               903
       Excess income tax benefit from exercise
        of stock options                              -            (4,984)
       Changes in operating assets and
        liabilities, net of acquisitions:
         Accounts receivable                    (16,256)             (153)
         Inventories                            (57,941)           (8,156)
         Other assets                            10,568             4,241
         Accounts payable                        47,219            13,927
         Accrued expenses and other
          liabilities                           (20,843)          (10,946)
           Net cash provided by operating
            activities                           56,226           114,813

    Cash flows from investing activities:
     Purchase of property, plant and equipment  (35,639)          (21,693)
     Purchase of available-for-sale investments       -          (159,884)
     Proceeds from sale of available-for-sale
      investments                                     -           248,728
     Cash paid for acquisitions, net of cash
      acquired                                     (264)           (5,072)
     Escrow refund, net of purchase price
      adjustments                                11,989                 -
           Net cash (used in) provided by
            investing activities                (23,914)           62,079

    Cash flows from financing activities:
     Principal payments under long-term debt
      agreements and capital leases             (16,785)             (481)
     Proceeds from borrowings under the
      Revolving Credit Facility                  60,000                 -
     Principal payments under the Revolving
      Credit Facility                          (115,000)                -
     Excess income tax benefit from exercise
      of stock options                                -             4,984
     Proceeds from stock options exercised            6             3,852
     Purchase of treasury stock (subsequently
      retired)                                        -          (171,008)
           Net cash used in financing
            activities                          (71,779)         (162,653)

    Effect of exchange rate changes on cash
     and cash equivalents                        (6,912)           (2,233)

    Net (decrease) increase in cash and cash
     equivalents                                (46,379)           12,006

    Cash and cash equivalents at beginning
     of period                                   90,180            92,902

    Cash and cash equivalents at end of period  $43,801          $104,908

    Contact: Harvey Kamil                      Carl Hymans
    NBTY, Inc.                                 G.S. Schwartz & Co.
    President and Chief Financial Officer      212-725-4500
    631-200-2020                               carlh@schwartz.com


'/>"/>
SOURCE NBTY, Inc.
Copyright©2009 PR Newswire.
All rights reserved


Related medicine news :

1. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
2. Haemacure Reports Third Quarter 2007 Results
3. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
4. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
5. MDS Reports Third Quarter 2007 Results
6. Allied Healthcare Reports Strong Fourth Quarter, Flat Net Income for Fiscal 2007 vs. 2006
7. AtriCure Reports First Human Implant of the Cosgrove-Gillinov Left Atrial Appendage Occlusion System
8. NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results
9. Blue Cross and Blue Shield of Florida Reports Eighteenth Consecutive Year of Positive Performance
10. ReBuilder Medical Technologies, Inc. Reports International Sales Expansion
11. AdCare Health Systems, Inc. Reports Discontinuation of Definitive Merger Agreement with Family Home Health Services, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... York, New York (PRWEB) , ... May 31, 2016 , ... ... effects research to provide the best accessories to avoid excessive Smartphone radiation implicated in ... of the study released on the bioRxiv preprint server on May 26th ...
(Date:5/31/2016)... ... June 01, 2016 , ... Psoriasis: Targets and Therapy ... , As corresponding author Professor Luigi Naldi says “The review in Psoriasis: Targets ... Smoking influences the onset and the severity of psoriasis, and negatively influences the ...
(Date:5/31/2016)... ... May 31, 2016 , ... Fire ... CDC, has joined the Fire Door Solutions’ team. Keith will serve Fire ... and frame in-field re-labeling. He will be instrumental in developing educational curriculum ...
(Date:5/31/2016)... ... May 31, 2016 , ... ... that considers individuals’ genetic characteristics and the physical and behavioral worlds in ... in sync. In personalized medicine, diagnosing an individual’s disease depends on accurately ...
(Date:5/31/2016)... CA (PRWEB) , ... May 31, 2016 , ... Throughout the day, adults often find ... sustained motivation and awareness, but what they could be reaching for instead is a cup ... plants that are grown in Japan. This sacred tea is harvested from early June to ...
Breaking Medicine News(10 mins):
(Date:5/30/2016)... The global  parenteral nutrition ... by 2024, according to a new report by ... the growing malnutrition coupled with the prevalence of ... diseases are expected to boost the market over ... http://photos.prnewswire.com/prnh/20150105/723757 ) , The presence ...
(Date:5/30/2016)... - DCGI grants limited approval to market Stempeucel® product for treating ... becomes 5th off-the-shelf Stem cell product to be approved by a ... (also known as Thromboangiitis Obliterans) is a major unmet medical need ... Prevalence of Buerger,s Disease is estimated to be 1,000,000 in ... European Community & USA Stempeutics ...
(Date:5/30/2016)... 2016 Eye expert s ... to seek an eye examination before ...   Moorfields Eye Hospital Dubai, the first overseas ... , has identified premature babies as a special concern in ... particular vulnerability to retinopathy of prematurity (ROP). ROP is a potentially ...
Breaking Medicine Technology: